• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.

作者信息

Zarogoulidis Paul, Papadopoulos Vasilis, Maragouli Elena, Papatsibas George, Sardeli Chrysanthi, Man Yan-Gao, Bai Chong, Huang Haidong

机构信息

Pulmonary Department-Oncology Unit, "Theageneio" Cancer Hospital, Thessaloniki, Greece.

Oncology Department, University of Thessaly, Larissa, Greece.

出版信息

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S28-S30. doi: 10.21037/tlcr.2018.01.04.

DOI:10.21037/tlcr.2018.01.04
PMID:29531900
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5835639/
Abstract
摘要

相似文献

1
Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.纳武利尤单抗作为非小细胞肺癌患者的一线治疗——关键因素：肿瘤突变负荷和程序性死亡受体配体1（PD-L1）≥50
Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S28-S30. doi: 10.21037/tlcr.2018.01.04.
2
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.新辅助 PD-1 阻断治疗可切除性肺癌。
N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16.
3
A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.在非鳞状非小细胞肺癌中，评估程序性细胞死亡配体 1 表达以预测纳武利尤单抗治疗患者反应时，单一活检样本中需要至少有 100 个肿瘤细胞。
J Thorac Oncol. 2019 Oct;14(10):1818-1827. doi: 10.1016/j.jtho.2019.06.019. Epub 2019 Jun 28.
4
Effect and biomarker of Nivolumab for non-small-cell lung cancer.纳武利尤单抗治疗非小细胞肺癌的疗效及生物标志物。
Biomed Pharmacother. 2019 Sep;117:109199. doi: 10.1016/j.biopha.2019.109199. Epub 2019 Jul 5.
5
Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.纳武利尤单抗治疗高肿瘤突变负荷的 SMARCA4 缺陷型非小细胞肺癌成功：一例报告。
Thorac Cancer. 2019 May;10(5):1285-1288. doi: 10.1111/1759-7714.13070. Epub 2019 Apr 10.
6
A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.一例伴有EGFR突变及周围PD-L1阳性肿瘤相关巨噬细胞的PD-L1阴性肺腺癌患者对纳武单抗的长期反应
Intern Med. 2019 Oct 15;58(20):3033-3037. doi: 10.2169/internalmedicine.2875-19. Epub 2019 Jul 10.
7
A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.基于多变量回归模型的列线图估算先前接受纳武利尤单抗治疗的晚期非小细胞肺癌患者的总生存期。
Anticancer Res. 2020 Aug;40(8):4229-4236. doi: 10.21873/anticanres.14424.
8
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.纳武利尤单抗治疗晚期非小细胞肺癌患者循环肿瘤细胞中 PD-L1 的表达。
Lung Cancer. 2018 Jun;120:108-112. doi: 10.1016/j.lungcan.2018.04.001. Epub 2018 Apr 3.
9
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.一例难治性转移性肺鳞状细胞癌患者在持久临床缓解前出现严重的纳武单抗诱导性肺炎：病例报告
J Hematol Oncol. 2017 Feb 28;10(1):64. doi: 10.1186/s13045-017-0433-z.
10
Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.化疗和纳武单抗治疗后PD-L1表达的阳性转化
Anticancer Res. 2017 Oct;37(10):5713-5717. doi: 10.21873/anticanres.12009.

引用本文的文献

1
Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy.用于非小细胞肺癌免疫治疗中肺炎诊断的冷冻活检
Respir Med Case Rep. 2022 Sep 15;39:101741. doi: 10.1016/j.rmcr.2022.101741. eCollection 2022.
2
RANBP9 as potential therapeutic target in non-small cell lung cancer.RANBP9作为非小细胞肺癌的潜在治疗靶点。
J Cancer Metastasis Treat. 2020;6. doi: 10.20517/2394-4722.2020.32. Epub 2020 Jun 24.
3
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.复发弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤或里氏转化患者对依鲁替尼加纳武单抗反应的生物标志物。
Transl Oncol. 2021 Jan;14(1):100977. doi: 10.1016/j.tranon.2020.100977. Epub 2020 Dec 6.
4
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.非小细胞肺癌的一线免疫检查点抑制剂：现状与未来进展
Front Pharmacol. 2020 Oct 7;11:578091. doi: 10.3389/fphar.2020.578091. eCollection 2020.
5
Antitumour dendritic cell vaccination in a priming and boosting approach.树突状细胞瘤苗接种在初步免疫和加强免疫中的应用。
Nat Rev Drug Discov. 2020 Sep;19(9):635-652. doi: 10.1038/s41573-020-0074-8. Epub 2020 Aug 6.
6
Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method.基于小范围二代测序靶向基因panel得出的肿瘤突变负荷作为一种初始筛查方法。
Transl Lung Cancer Res. 2020 Feb;9(1):71-81. doi: 10.21037/tlcr.2019.12.27.
7
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].[肺癌中PD-1/PD-L1检查点抑制剂的研究进展]
Zhongguo Fei Ai Za Zhi. 2019 Jun 20;22(6):369-379. doi: 10.3779/j.issn.1009-3419.2019.06.07.
8
Inhaled Cisplatin for NSCLC: Facts and Results.吸入用顺铂治疗非小细胞肺癌：现状与结果。
Int J Mol Sci. 2019 Apr 24;20(8):2005. doi: 10.3390/ijms20082005.

本文引用的文献

1
ASCO update: lung cancer.美国临床肿瘤学会（ASCO）最新消息：肺癌
Memo. 2017;10(4):224-227. doi: 10.1007/s12254-017-0373-x. Epub 2017 Dec 1.
2
Radiotherapy: the key to immunotherapy ignition?放射治疗：启动免疫治疗的关键？
Oncotarget. 2017 Oct 25;8(55):93307-93308. doi: 10.18632/oncotarget.22070. eCollection 2017 Nov 7.
3
Multiple guided technologies based on radial probe endobronchial ultrasound for the diagnosis of solitary peripheral pulmonary lesions: a single-center study.基于径向探头支气管内超声的多种引导技术用于孤立性周围型肺病变的诊断：一项单中心研究
J Cancer. 2017 Sep 29;8(17):3514-3521. doi: 10.7150/jca.20035. eCollection 2017.
4
The novel 19G endobronchial USS (EBUS) needle samples processed as tissue "core biopsies" facilitate PD-L1 and other biomarker testing in lung cancer specimens: case report and the view point from the Respiratory Physician and the Pathologist.将新型19G支气管内超声（EBUS）针样本作为组织“芯活检”进行处理，有助于肺癌标本中的程序性死亡配体1（PD-L1）及其他生物标志物检测：病例报告以及呼吸内科医生和病理科医生的观点
Respirol Case Rep. 2017 Sep 10;5(6):e00271. doi: 10.1002/rcr2.271. eCollection 2017 Nov.
5
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.纳武利尤单抗免疫治疗期间的肿瘤与微环境演变
Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.
6
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.非小细胞肺癌中程序性死亡受体配体1（PD-L1）的表达：细胞学、小活检及手术切除标本的比较
Cancer Cytopathol. 2017 Dec;125(12):896-907. doi: 10.1002/cncy.21937. Epub 2017 Oct 12.
7
Evolution analysis of heterogeneous non-small cell lung carcinoma by ultra-deep sequencing of the mitochondrial genome.通过对线粒体基因组的超高深度测序分析异质性非小细胞肺癌。
Sci Rep. 2017 Sep 11;7(1):11069. doi: 10.1038/s41598-017-11345-3.
8
Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.免疫疗法“冲击”：一组程序性死亡受体配体1（PD-L1）表达为100%且帕博利珠单抗一线治疗的病例系列
Respir Med Case Rep. 2017 Aug 29;22:197-202. doi: 10.1016/j.rmcr.2017.08.017. eCollection 2017.
9
Endobronchial ultrasound convex probe for lymphoma, sarcoidosis, lung cancer and other thoracic entities. A case series.用于淋巴瘤、结节病、肺癌及其他胸部疾病的支气管内超声凸阵探头。病例系列报道。
Respir Med Case Rep. 2017 Aug 19;22:187-196. doi: 10.1016/j.rmcr.2017.08.016. eCollection 2017.
10
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.IV 期非小细胞肺癌的系统治疗：美国临床肿瘤学会临床实践指南更新。
J Clin Oncol. 2017 Oct 20;35(30):3484-3515. doi: 10.1200/JCO.2017.74.6065. Epub 2017 Aug 14.